Wesbanco Bank Inc. Buys Shares of 64,000 Intellia Therapeutics, Inc. $NTLA

Wesbanco Bank Inc. bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the fourth quarter, HoldingsChannel.com reports. The fund bought 64,000 shares of the company’s stock, valued at approximately $575,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NTLA. AQR Capital Management LLC boosted its stake in Intellia Therapeutics by 154.1% in the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after acquiring an additional 55,118 shares during the period. Woodline Partners LP acquired a new position in shares of Intellia Therapeutics during the first quarter worth approximately $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after buying an additional 38,521 shares during the period. Creative Planning boosted its position in shares of Intellia Therapeutics by 12.9% during the second quarter. Creative Planning now owns 33,102 shares of the company’s stock worth $310,000 after buying an additional 3,795 shares during the period. Finally, Cetera Investment Advisers boosted its position in shares of Intellia Therapeutics by 47.4% during the second quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after buying an additional 10,785 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Tuesday, April 21st. William Blair upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday, March 2nd. Morgan Stanley boosted their price objective on Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Monday, April 27th. The Goldman Sachs Group boosted their price objective on Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research report on Tuesday, April 28th. Finally, Citizens Jmp boosted their price objective on Intellia Therapeutics from $28.00 to $30.00 and gave the stock a “market outperform” rating in a research report on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $20.55.

Intellia Therapeutics Price Performance

NTLA opened at $14.09 on Monday. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -3.68 and a beta of 1.93. Intellia Therapeutics, Inc. has a 1-year low of $6.83 and a 1-year high of $28.25. The business has a 50 day moving average price of $13.65 and a two-hundred day moving average price of $12.41.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. The firm had revenue of $23.02 million during the quarter, compared to the consensus estimate of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.27) earnings per share. Equities analysts expect that Intellia Therapeutics, Inc. will post -3.5 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.